Table 1 Baseline characteristics of the patients

Age, y

61.1 ± 15.1

61.2 ± 11.5

Sex, male, n (%)

349 (62.1)

187 (69.5)

Body mass index, kg/m²

29.0 ± 5.8

30.9 ± 5.6

Previous medical history, %

 Smokers

35.1

38.8

 Alcohol

19.3

12.8

 Arterial hypertension

42.5

49.8

 Ischemic cardiopathy

7.3

7.5

 Pulmonary embolism

3.9

3.4

 Deep vein thrombosis

4.8

3.4

 Diabetes

23

33.5

 COPD

6.2

3.3

 Asthma

8.50

5.6

 Obstructive sleep apnea

10

8.6

 Cancer

10.7

7.8

 Immunosuppression

3.7

4.1

Daily treatments, %

 Inhibitors of angiotensin converting enzyme

15.2

15.6

 Aldosterone antagonists

15.7

16.4

 Beta-blockers

18.4

19.3

 Corticosteroids

8.4

7.1

 Immunosuppressors

2.7

3

 Antiplatelets agents

14.4

11.9

 Anticoagulants

11.4

8.1

COVID-19 symptoms, %

 Fever

69.4

65

 Asthenia

73.3

59

 Cough

72.2

62.9

 Dyspnea

70.3

81.6

 Chest pain

20.8

11

 Myalgia

35.5

25.5

 Diarrhoea

36.1

27.9

 Vomiting

22.4

14.7

 Headache

30.6

17.2

 Cutaneous rash

2.8

2.7

 Ageusia

24.6

13.7

 Anosmia

20.7

13.7

pH

7.50 (7.40–7.50)

7.50 (7.40–7.50)

PaO₂, mmHg

71.1 (62.3–84)

72.9 (61.6–88.2)

PaCO₂, mmHg

34.5 (31.2–37.5)

34.0 (30.0–39.1)

PaO₂/FiO₂

286 (188–331)

102.0 (80.5–155.5)

Supplemental Oxygen < 5L/min, %

91.3

Supplemental Oxygen > 5L/min, %

5.1

High flow oxygenation, %

3.6

60.6

Invasive mechanical ventilation, %

0

30.5

Vasopressors, %

0

10

Extra renal therapy, %

0

0.4

Antibiotics, %

20.3

37.5

sTREM-1, pg/mL

147 (76–249)

224 (144–320)

Interleukin-6, pg/mL

16 (7–36)

45 (15–98)

Interleukin-1b, pg/mL

0.2 (0.2–0.2)

Interleukin-8, pg/mL

20 (14–31)

Interleukin-10, pg/mL

13 (8–22)

Interferon-γ, pg/mL

4 (1–10)

Chemokine ligand-2, pg/mL

363 (282–691)

Angiopoietin-2, pg/mL

1298 (896–2010)